Business Context and Reporting Period
This Form 8-K is a current report filed by Fluidigm Corporation (not Standard BioTools Inc.) on January 10, 2013. The filing reports the election of a new director to the company's board of directors.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and director compensation arrangements.
Material Changes
The primary material change reported is the election of Gerhard F. Burbach as a Class II director on January 10, 2013, to fill a vacant seat. Mr. Burbach will also serve as a member of the audit and compensation committees.
Guidance, Outlook, and Compensation Details
There is no financial guidance or outlook provided in this filing. The document details the compensation package for the newly elected director:
- Cash Compensation: Base annual retainer of $20,000 for non-employee directors. Additional retainers apply for committee service (Audit: $10,000; Compensation: $7,000; Nominating: $5,000) and committee chair roles.
- Equity Compensation: Mr. Burbach was granted an option to purchase 30,000 shares of common stock on the date of election. He will receive an annual option grant for 12,000 shares at each subsequent annual meeting, contingent on continued service.
- Indemnification: An indemnification agreement was entered into on January 10, 2013.
Investor Verification Checklist
- Verify the identity of the registrant as Fluidigm Corporation, noting the discrepancy with the metadata field "STANDARD BIOTOOLS INC."
- Confirm the background and qualifications of the new director, Gerhard F. Burbach, particularly his experience at Thoratec Corporation and Digirad Corporation.
- Review the definitive proxy statement on Schedule 14A (filed March 26, 2012) for the full terms of the non-employee director compensation program.
- Check the press release dated January 14, 2013 (Exhibit 99.1) for additional public commentary on the appointment.